This indicates that B-cell lymphomas might necessitate stratification into PDE4B-high and PDE4B-low expression groups to facilitate personalized combination therapies incorporating PDE4 inhibitors. Here, PDE4B is linked to B-cell non-Hodgkin lymphoma.